MedTrace Logo

A Study With ASP2151 in Subjects With Recurrent Episodes of Genital Herpes

NCT00486200 · Status: COMPLETED · Phase: PHASE2 · Type: INTERVENTIONAL · Enrollment: 695

Last updated 2017-12-07

No results posted yet for this study

Summary

A study of ASP2151 in subjects with recurrent outbreaks of genital herpes.

Conditions

  • Herpes Genitalis

Interventions

DRUG

ASP2151

Oral administration.

DRUG

valacyclovir

Oral administration of active comparator.

DRUG

Placebo

Oral administration of placebo.

Sponsors & Collaborators

  • Astellas Pharma Inc

    lead INDUSTRY

Principal Investigators

  • Use Central Contact · Astellas Pharma US, Inc.

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
QUADRUPLE
Model
PARALLEL

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2007-06-21
Primary Completion
2008-08-12
Completion
2008-08-12

Countries

  • United States

Study Locations

More Related Trials

Entities

Drugs

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT00486200 on ClinicalTrials.gov